A 58 year-old woman was diagnosed with lung adenocarcinoma (cT3N1M0). We detected a point mutation in epidermal growth factor receptor (EGFR) exon 21 (L858R) and an echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (ALK) rearrangement. The patient was treated with preoperative neoadjuvant chemotherapy and underwent a left lower lobectomy with mediastinal lymph node dissection. However, we could not detect any mutation in EGFR or the ALK rearrangement from the tumor tissue removed. Then, 70 days after completion of adjuvant chemotherapy, she visited our outpatient clinic with diminished visual accuracy and tinnitus. A single brain metastatic lesion was seen on brain magnetic resonance imaging. She underwent surgical removal of the brain mass, which showed a mutation of EGFR, exon 21, but no ALK rearrangement. We report this unusual case of lung adenocarcinoma with a coexisting EGFR mutation and ALK rearrangement, and identify gene alterations before chemotherapy, after chemotherapy, and at recurrence. (Korean J Med 2016;90:72-77) 
EGFR 돌연변이와 ALK 재배열 공존하는 폐선암 환자 1예
.
Recent studies have revealed high intra-tumoral heterogeneity of multiple tumor-suppressor genes and inter-tumoral heterogeneity between primary and corresponding metastatic tumors [4] . Because tumor heterogeneity has a great impact on future anti-cancer treatment strategies, its clinical implications require further investigation.
In this case, we examined the status of EGFR mutations and the ALK rearrangement before chemotherapy, after chemotherapy, and at recurrence, and identified that the genetic alterations at 1F ). We examined the EGFR mutation and ALK rearrangement in the metastatic tumor tissue, which revealed a point mutation of EGFR exon 21 (L858R) (Fig. 2C ), but no ALK rearrangement (Fig. 3C) .
DISCUSSION
Over the last decade, significant advances have been made in the identification of oncogenic driver mutations playing key roles in tumor initiation and progression in non small cell lung carcinoma (NSCLC). Among the well-known driver mutations, EGFR mutations and ALK fusions have been regarded as biological determinants for the selection of specific targeted agents [5, 6] . Generally, these two genetic alterations have been considered to be mutually exclusive [7] . However, the coexistence of these two oncogenic driver mutations has been reported in rare cases (0.330.97%) [8] . The proportion of patients harboring concomitant EGFR and ALK alterations is currently increasing, resulting from clinical application of highly sensitive detection tools for EGFR mutations [9] .
This case was a female patient with a lung adenocarcinoma harboring both an EGFR mutation and an ALK rearrangement at the initial presentation. It was notable that the genetic alterations were different in the primary tumor before chemotherapy, after surgical removal, and at recurrence ( Table 1 As shown in our case and a previous study [10] , single-gene 중심 단어: EGFR; ALK; 폐선암
